Skip to main content
. 2010 Jun 30;299(3):C539–C548. doi: 10.1152/ajpcell.00047.2010

Fig. 1.

Fig. 1.

Illustration of the means by which tetracyclines may lose their protein synthesis inhibitory capacity in pathogens such as bacteria. This may occur secondary to the enhanced extrusion of the drug, decreased entry, displacement from the target (ribosomes), or enzymatic inactivation.